Ensysce Biosciences secures second financing from 2025 agreement

Ensysce Biosciences (ENSC) announced the closing of a second convertible preferred stock financing of $2M under prior commitment in November 2025 of up to $20M funding available over 24 months. The capital will maintain Ensysce’s flagship analgesic programs, while supporting general corporate initiatives. The current $2M tranche includes a fixed conversion price of $0.55 per share, with an alternate conversion price based upon average common stock prices prior to conversion. The financing includes 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term, each exercisable at the fixed conversion price, subject to adjustment.